Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment

Status:
Completed

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Assessment of the effect of normal and impaired kidney function on the pharmacokinetics, pharmacodynamics and safety of BI 10773

Phase 1

Boehringer Ingelheim

Empagliflozin